{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"peripheral-neuropathy","verification":{"valid":true,"entries":7,"head":"4c66a419a7df719c3bdb943b4b4133ccdc9d3dc86ce615ea235355d830f90160"},"count":7,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42035456/","external_id":"42035456","pmid":"42035456","title":"Metformin-Associated Functional Vitamin B12 Deficiency Presenting as Subacute Combined Degeneration in a 57-Year-Old Man With Diabetes Mellitus","quote":"CONCLUSIONS This case of metformin-associated cobalamin deficiency with subacute combined degeneration of the spinal cord highlights the importance of monitoring vitamin B12 status and neurological sy","summary":"American Journal of Case Reports 2026: nerve and spinal cord damage from B12 deficiency caused by long-term metformin, which improved substantially within weeks of treatment. The commonest missed reversible cause in people who already have a diabetes label.","author":"Zhang R, Gou L et al.","publisher":"The American journal of case reports","date":"2026","tag":"Case report","accessed_at":"2026-08-05T01:41:58.243Z","prev":"genesis","hash":"09d9d89b36f25d0a23b4b4bf379e607925240122d1562218a2b517205ca498e5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42043615/","external_id":"42043615","pmid":"42043615","title":"Heterogeneous course of diabetic polyneuropathy in type 1 diabetes over 5 years: is regression possible?","quote":"CONCLUSIONS: Over 5 years the overall prevalence of DPN increased; however, regression to less severe DPN or complete absence of DPN occurred.","summary":"Endocrine 2026: five years of follow-up in type 1 diabetes. Prevalence rose across the group while individuals moved both ways — some to less severe disease, some out of the diagnosis entirely. The authors conclude continued intervention remains worthwhile well after diagnosis.","author":"Pertile P, D'Ippolito I et al.","publisher":"Endocrine","date":"2026","tag":"Cohort study","accessed_at":"2026-08-05T01:41:58.243Z","prev":"09d9d89b36f25d0a23b4b4bf379e607925240122d1562218a2b517205ca498e5","hash":"e8442138d5b22942839d89ec1f45729f2cfb331d862835a6740f42b77d4cdfb6"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41364419/","external_id":"41364419","pmid":"41364419","title":"Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives","quote":"Every diabetes clinic should perform annual screening for DPN to identify the risk of diabetic foot disease using a monofilament and tuning fork (or biothesiometer).","summary":"Drugs & Aging 2026: the agreed screening method, requiring two instruments that cost almost nothing, done once a year.","author":"Dubský M, Sojáková D et al.","publisher":"Drugs & aging","date":"2026","tag":"Review","accessed_at":"2026-08-05T01:41:58.243Z","prev":"e8442138d5b22942839d89ec1f45729f2cfb331d862835a6740f42b77d4cdfb6","hash":"ec8d701cceaf0e41835fb9e142ef47221b5781ee2383f4ba0821cb25243a9bd8"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42063783/","external_id":"42063783","pmid":"42063783","title":"Risk factors for diabetic at-risk foot disease among the diabetes over 60 years old: a cross-sectional study","quote":"Notably, peripheral neuropathy (PN) significantly increased the probability of at-risk foot condition by approximately 882.9% (OR = 9.829, 95% CI: 4.607-20.969, p ConclusionA high percentage of people","summary":"Frontiers in Medicine 2026: in people over 60 with diabetes, neuropathy raised the odds of an at-risk foot roughly ninefold. Numbness means an injury does not announce itself.","author":"Wu M, Xiao S et al.","publisher":"Frontiers in medicine","date":"2026","tag":"Cross-sectional study","accessed_at":"2026-08-05T01:41:58.243Z","prev":"ec8d701cceaf0e41835fb9e142ef47221b5781ee2383f4ba0821cb25243a9bd8","hash":"d8bdae4fbe43c52bd9298579b8c19da4ecac68dd8b8667758c89b43264e65b1c"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41364419/","external_id":"41364419","pmid":"41364419","title":"Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives","quote":"The treatment of diabetic neuropathy remains limited, as studies on causal therapy have shown conflicting results.","summary":"The same review on what the drugs are for: treatment of the underlying nerve damage remains limited, so most of it is glucose control plus symptom management.","author":"Dubský M, Sojáková D et al.","publisher":"Drugs & aging","date":"2026","tag":"Review","accessed_at":"2026-08-05T01:41:58.243Z","prev":"d8bdae4fbe43c52bd9298579b8c19da4ecac68dd8b8667758c89b43264e65b1c","hash":"59e5071c098897d89b6e144673de4d5cd65add139925cc4f85892bc69a88b69e"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39544662/","external_id":"39544662","pmid":"39544662","title":"Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study","quote":"Pregabalin was superior to amitriptyline and duloxetine, whereas it was comparable to gabapentin in effectiveness.","summary":"Annals of Neurosciences 2026: a head-to-head of the first-line drugs. The same trial counted 14 adverse events in total, the largest share of them in the duloxetine arm.","author":"Balasundaram MK, Kannauje PK et al.","publisher":"Annals of neurosciences","date":"2026","tag":"Randomised comparison","accessed_at":"2026-08-05T01:41:58.243Z","prev":"59e5071c098897d89b6e144673de4d5cd65add139925cc4f85892bc69a88b69e","hash":"e1a7633c36d52a610cc18dcbf4a6f313cb6b58caa15e6bcc586074c617c14c81"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39839199/","external_id":"39839199","pmid":"39839199","title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety","quote":"In conclusion, pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did.","summary":"Frontiers in Pain Research 2024: pooled analysis separating the two drugs that came out on top — pregabalin worked better and sooner, with lower opioid use and fewer adverse events.","author":"Mayoral V, Galvez R et al.","publisher":"Frontiers in pain research (Lausanne, Switzerland)","date":"2024","tag":"Meta-analysis","accessed_at":"2026-08-05T01:41:58.243Z","prev":"e1a7633c36d52a610cc18dcbf4a6f313cb6b58caa15e6bcc586074c617c14c81","hash":"4c66a419a7df719c3bdb943b4b4133ccdc9d3dc86ce615ea235355d830f90160"}]}